These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 35760586)
41. Dexamethasone Intravitreal Implant Injection in Eyes with Comorbid Hypotony. Kong X; Psaras C; Stewart JM Ophthalmol Retina; 2019 Nov; 3(11):993-997. PubMed ID: 31371197 [TBL] [Abstract][Full Text] [Related]
42. [Treatment of Macular Oedema due to retinal vein occlusion with OZURDEX]. Studnička J; Dusová J; Skoupá J; Řehák J Cesk Slov Oftalmol; 2015 Aug; 71(4):199-203. PubMed ID: 26395854 [TBL] [Abstract][Full Text] [Related]
43. Intravitreal dexamethasone implant Ozurdex in the treatment of diabetic macular edema in patients not previously treated with any intravitreal drug: a prospective 12-month follow-up study. Menezo M; Roca M; Menezo V; Pascual I Curr Med Res Opin; 2019 Dec; 35(12):2111-2116. PubMed ID: 31378087 [No Abstract] [Full Text] [Related]
44. Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion. Michalska-Małecka K; Gaborek A; Nowak M; Halat T; Pawłowska M; Śpiewak D Clin Interv Aging; 2016; 11():699-705. PubMed ID: 27307716 [TBL] [Abstract][Full Text] [Related]
45. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239 [TBL] [Abstract][Full Text] [Related]
46. DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF RECALCITRANT MACULAR EDEMA AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR. Thanos A; Todorich B; Yonekawa Y; Papakostas TD; Khundkar T; Eliott D; Dass AB; Williams GA; Capone A; Faia LJ; Wolfe JD; Hassan TS; Ruby AJ Retina; 2018 Jun; 38(6):1084-1090. PubMed ID: 28622270 [TBL] [Abstract][Full Text] [Related]
47. Anterior chamber migration of dexamethasone intravitreal implant (Ozurdex®) through basal iridectomy (Ando) in a pseudophakic patient. Stepanov A; Codenotti M; Ramoni A; Prati M; Jiraskova N; Rozsival P; Bandello F Eur J Ophthalmol; 2016 Apr; 26(3):e52-4. PubMed ID: 26615950 [TBL] [Abstract][Full Text] [Related]
48. Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: a case report. Sharma A; Madhusudhan RJ; Nadahalli V; Damgude SA; Sundaramoorthy SK Indian J Ophthalmol; 2012; 60(3):234-5. PubMed ID: 22569393 [TBL] [Abstract][Full Text] [Related]
49. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch. Ruiz-Medrano J; Rodríguez-Leor R; Almazán E; Lugo F; Casado-Lopez E; Arias L; Ruiz-Moreno JM Eur J Ophthalmol; 2021 May; 31(3):1135-1145. PubMed ID: 32493065 [TBL] [Abstract][Full Text] [Related]
50. Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study. Fonollosa A; Zarranz-Ventura J; Valverde A; Becerra E; Bernal-Morales C; Pastor-Idoate S; Zapata MA Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2381-2390. PubMed ID: 31451909 [TBL] [Abstract][Full Text] [Related]
51. Pars plana vitrectomy and re-directing a dexamethasone implant into vitreous cavity following misdirected entry into the crystalline lens. Biswas P; Nandi K; Batra S; Ginodia A; Biswas P Indian J Ophthalmol; 2018 Jul; 66(7):1033-1036. PubMed ID: 29941766 [TBL] [Abstract][Full Text] [Related]
52. The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario. Simsek M; Citirik M; Ozates S; Ozkoyuncu D Indian J Ophthalmol; 2018 Jun; 66(6):831-836. PubMed ID: 29785994 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion. Donati S; Gandolfi C; Caprani SM; Cattaneo J; Premoli L; Azzolini C Biomed Res Int; 2018; 2018():3095961. PubMed ID: 30175123 [TBL] [Abstract][Full Text] [Related]
54. The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial. Mehta H; Fraser-Bell S; Nguyen V; Lim LL; Gillies MC Ophthalmol Retina; 2018 Mar; 2(3):231-234. PubMed ID: 31047591 [TBL] [Abstract][Full Text] [Related]
55. Intravitreal steroids for macular edema in diabetes. Rittiphairoj T; Mir TA; Li T; Virgili G Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392 [TBL] [Abstract][Full Text] [Related]
56. Cystic roof collapse after intravitreal injection of dexamethasone implant, a case report. Romano F; Albertini GC; Arrigo A; Battaglia Parodi M; Bandello F Eur J Ophthalmol; 2019 Jul; 29(4):NP16-NP18. PubMed ID: 30353744 [TBL] [Abstract][Full Text] [Related]
57. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. Castro-Navarro V; Cervera-Taulet E; Navarro-Palop C; Monferrer-Adsuara C; Hernández-Bel L; Montero-Hernández J BMC Ophthalmol; 2019 Jan; 19(1):15. PubMed ID: 30634940 [TBL] [Abstract][Full Text] [Related]
58. Immortal Ozurdex: A 10-month follow-up of an intralenticular implant. Poornachandra B; Kumar VBM; Jayadev C; Dorelli SH; Yadav NK; Shetty R Indian J Ophthalmol; 2017 Mar; 65(3):255-257. PubMed ID: 28440260 [TBL] [Abstract][Full Text] [Related]